Phytochemicals in Alzheimer disease: The development of clinical trials

被引:5
|
作者
Quinn, J
Kaye, J
Montine, T
Stackman, R
机构
[1] Portland VA Med Ctr, Dept Neurol, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA
[3] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA
关键词
Alzheimer disease; antioxidants; oxidative stress; polyphenolics;
D O I
10.3109/138802090893531
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Polyphenolics and other phytochemicals may have a role in the prevention or treatment of Alzheimer disease. Targets of therapy in Alzheimer disease include neurotransmitter deficits, beta amyloid neurotoxicity, oxidative damage, and inflammation, to name a few. Challenges to the development of phytochemical and other neuroprotectant therapy in Alzheimer disease include the inability to measure pathology in living patients and the challenge of detecting modification of an indolent disease course. These challenges are partially surmounted by the use of animal models and of biomarkers of disease. This review describes currently available animal models and biomarkers and surveys clinical trials of phytochemical therapies that. are recently completed or currently under way. Both animal studies and clinical trials of Ginkgo biloba are described, as well as a trial of Uncaria tomentosa that has not been previously reported.
引用
收藏
页码:64 / 73
页数:10
相关论文
共 50 条
  • [1] Alzheimer's disease: clinical trials and drug development
    Mangialasche, Francesca
    Solomon, Alina
    Winblad, Bengt
    Mecocci, Patrizia
    Kivipelto, Miia
    LANCET NEUROLOGY, 2010, 9 (07): : 702 - 716
  • [2] The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs
    Cummings, Jeffrey
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2020, 7 (04): : 288 - 290
  • [3] The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
    Jeffrey Cummings
    The Journal of Prevention of Alzheimer's Disease, 2020, 7 : 288 - 290
  • [4] Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development
    Cummings, Jeffrey L.
    Osse, Amanda M. Leisgang
    Kinney, Jefferson W.
    Cammann, Davis
    Chen, Jingchun
    CNS DRUGS, 2024, 38 (08) : 613 - 624
  • [5] Recruitment of Subjects Into Clinical Trials for Alzheimer Disease
    Knebl, Janice A.
    Patki, Deepti
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2010, 110 (09): : S43 - S49
  • [6] Clinical trials of new drugs for Alzheimer disease
    Li-Kai Huang
    Shu-Ping Chao
    Chaur-Jong Hu
    Journal of Biomedical Science, 27
  • [7] Clinical Methodology of Alzheimer’s Disease Trials
    Julian A. Gray
    Drug information journal : DIJ / Drug Information Association, 1999, 33 (1): : 245 - 252
  • [8] Clinical Trials and Alzheimer's Disease: A Webliography
    Howard, Allison
    JOURNAL OF CONSUMER HEALTH ON THE INTERNET, 2014, 18 (01) : 67 - 80
  • [9] Behavioral outcomes in clinical trials for Alzheimer disease
    Ferris, SH
    Mackell, JA
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1997, 11 : S10 - S15
  • [10] The role of biomarkers in clinical trials for Alzheimer disease
    Thal, LJ
    Kantarci, K
    Reiman, EM
    Klunk, WE
    Weiner, MW
    Zetterberg, H
    Galasko, D
    Praticò, D
    Griffin, S
    Schenk, D
    Siemers, E
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2006, 20 (01): : 6 - 15